[go: up one dir, main page]

BRPI0914927B8 - compound, pharmaceutical composition and use of a compound - Google Patents

compound, pharmaceutical composition and use of a compound

Info

Publication number
BRPI0914927B8
BRPI0914927B8 BRPI0914927A BRPI0914927A BRPI0914927B8 BR PI0914927 B8 BRPI0914927 B8 BR PI0914927B8 BR PI0914927 A BRPI0914927 A BR PI0914927A BR PI0914927 A BRPI0914927 A BR PI0914927A BR PI0914927 B8 BRPI0914927 B8 BR PI0914927B8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
medicines
cancer
function
Prior art date
Application number
BRPI0914927A
Other languages
Portuguese (pt)
Inventor
Christophe Barlaam Bernard
David Jones Clifford
Michael Foote Kevin
Ple Patrick
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0914927A2 publication Critical patent/BRPI0914927A2/en
Publication of BRPI0914927B1 publication Critical patent/BRPI0914927B1/en
Publication of BRPI0914927B8 publication Critical patent/BRPI0914927B8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

composto, composição farmacêutica, métodos para inibir a função de fak e de tratamento de um câncer, uso de um composto, e, processo para preparar um composto. a presente invenção diz respeito a compostos que inibem a função cinase de adesão focal, processos para a sua preparação, composições farmacêuticas que as contenham como o ingrediente ativo, ao seu uso como medicamentos e ao seu uso na fabricação de medicamentos para o uso no tratamento em animais de sangue quente tais como seres humanos de doenças tais como câncer.compound, pharmaceutical composition, methods for inhibiting fak function and treating a cancer, use of a compound, and, process for preparing a compound. the present invention concerns compounds that inhibit the focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, their use as medicines and their use in the manufacture of medicines for use in treatment in warm-blooded animals such as humans from diseases such as cancer.

BRPI0914927A 2008-06-17 2009-06-15 compound, pharmaceutical composition and use of a compound BRPI0914927B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7305508P 2008-06-17 2008-06-17
US61/073055 2008-06-17
PCT/GB2009/050675 WO2009153589A1 (en) 2008-06-17 2009-06-15 Pyridine compounds

Publications (3)

Publication Number Publication Date
BRPI0914927A2 BRPI0914927A2 (en) 2017-06-20
BRPI0914927B1 BRPI0914927B1 (en) 2020-10-06
BRPI0914927B8 true BRPI0914927B8 (en) 2021-05-25

Family

ID=40896110

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914927A BRPI0914927B8 (en) 2008-06-17 2009-06-15 compound, pharmaceutical composition and use of a compound

Country Status (17)

Country Link
US (1) US8569298B2 (en)
EP (1) EP2303861B1 (en)
JP (1) JP5551689B2 (en)
KR (1) KR101695501B1 (en)
CN (1) CN102124000B (en)
AU (1) AU2009261764B2 (en)
BR (1) BRPI0914927B8 (en)
CA (1) CA2726508C (en)
CR (1) CR11854A (en)
DO (1) DOP2010000390A (en)
EA (1) EA020807B1 (en)
EC (1) ECSP10010695A (en)
ES (1) ES2472323T3 (en)
IL (1) IL209727A0 (en)
MX (1) MX2010014057A (en)
WO (1) WO2009153589A1 (en)
ZA (1) ZA201100388B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3384482B2 (en) 1997-03-18 2003-03-10 本田技研工業株式会社 Piston ring supply device
JO3067B1 (en) 2008-10-27 2017-03-15 Glaxosmithkline Llc Pyrimidine amino pyrimidines as inhibitors for FAK
US20140155410A1 (en) * 2008-10-27 2014-06-05 Glaxosmithkline Llc Pyrazolylaminopyridines as inhibitors of fak
WO2010068947A2 (en) * 2008-12-12 2010-06-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Nuclear export inhibitors of topoisomerase ii alpha
LT2464645T (en) 2009-07-27 2017-10-25 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
RU2528386C2 (en) 2010-05-21 2014-09-20 Кемилиа Аб New pyrimidine derivatives
JP5936609B2 (en) 2010-06-29 2016-06-22 ベラステム インコーポレイテッド Oral preparation of kinase inhibitor
NZ604801A (en) * 2010-06-30 2015-03-27 Verastem Inc Synthesis and use of focal adhesion kinase inhibitors
US8703759B2 (en) 2010-07-02 2014-04-22 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
CA2825790A1 (en) * 2011-01-26 2012-08-02 Board Of Regents The University Of Texas System Combinations
WO2012110773A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
CA2827172C (en) 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
CA2830129C (en) 2011-03-24 2016-07-19 Chemilia Ab Novel pyrimidine derivatives
KR20140033377A (en) 2011-05-10 2014-03-18 길리애드 사이언시즈, 인코포레이티드 Fused heterocyclic compounds as sodium channel modulators
NO3175985T3 (en) 2011-07-01 2018-04-28
UY34171A (en) 2011-07-01 2013-01-31 Gilead Sciences Inc FUSIONED HETEROCYCLIC COMPOUNDS AS IONIC CHANNEL MODULATORS
CN104302640A (en) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-diaminopyrazole kinase inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
BR112016029612B1 (en) * 2014-06-17 2021-01-19 Pfizer Inc. substituted dihydroisoquinolinone compounds
US9442005B2 (en) * 2014-07-30 2016-09-13 Corning Optical Communications LLC Non-contact methods of measuring insertion loss in optical fiber connectors
HUE049801T2 (en) 2014-12-23 2020-10-28 Sma Therapeutics Inc 3,5-diaminopyrazole kinase inhibitors
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
CA3244408A1 (en) 2015-06-29 2025-06-13 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
US20180339985A1 (en) 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
KR102730587B1 (en) 2018-02-28 2024-11-14 바스프 에스이 Use of N-functionalized alkoxy pyrazole compounds as nitrification inhibitors
WO2019166558A1 (en) 2018-02-28 2019-09-06 Basf Se Use of pyrazole propargyl ethers as nitrification inhibitors
CN112218658A (en) 2018-03-12 2021-01-12 国家健康科学研究所 Use of caloric restriction mimics for chemoimmunotherapy to enhance cancer treatment
CN108912095B (en) * 2018-08-09 2019-08-20 广州安岩仁医药科技有限公司 Benzimidazoles compound and its preparation method and application
CN113811300B (en) * 2019-03-15 2024-10-29 总医院公司 Novel small molecule inhibitors of TEAD transcription factors
AU2020365108A1 (en) * 2019-10-18 2022-04-21 Atengen, Inc. 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders
US20240270658A1 (en) 2021-05-21 2024-08-15 Basf Se Use of an N-Functionalized Alkoxy Pyrazole Compound as Nitrification Inhibitor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
DE10336184A1 (en) 2003-08-07 2005-02-24 Bayer Materialscience Ag New catalysts for selective isocyanate dimerization
EP2287156B1 (en) * 2003-08-15 2013-05-29 Novartis AG 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
CA2571482A1 (en) 2004-06-21 2005-12-29 Pharmacia & Upjohn Company Llc Pyk2 inhibitors for stimulation of osteoblast function
GB0419160D0 (en) 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US8722884B2 (en) * 2005-12-01 2014-05-13 Verastem, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
RS20080272A (en) 2005-12-21 2009-07-15 Pfizer Products Inc., Pyramidine derivatives for the treatment of abnormal cell growth
PL2091918T3 (en) 2006-12-08 2015-02-27 Novartis Ag Compounds and compositions as protein kinase inhibitors
DK2134689T3 (en) * 2007-03-16 2014-06-30 Scripps Research Inst Focal adhesion kinase inhibitors
AU2008276063B2 (en) * 2007-07-17 2013-11-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP2011512413A (en) * 2008-02-19 2011-04-21 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Anilinopyridine as an inhibitor of FAK

Also Published As

Publication number Publication date
US8569298B2 (en) 2013-10-29
EA201100032A1 (en) 2012-01-30
BRPI0914927B1 (en) 2020-10-06
EP2303861A1 (en) 2011-04-06
DOP2010000390A (en) 2011-01-15
AU2009261764B2 (en) 2013-01-10
MX2010014057A (en) 2011-03-21
KR101695501B1 (en) 2017-01-11
CA2726508C (en) 2016-06-07
WO2009153589A1 (en) 2009-12-23
ECSP10010695A (en) 2011-01-31
KR20110023884A (en) 2011-03-08
IL209727A0 (en) 2011-02-28
AU2009261764A1 (en) 2009-12-23
CR11854A (en) 2011-02-25
JP5551689B2 (en) 2014-07-16
CN102124000A (en) 2011-07-13
ES2472323T3 (en) 2014-06-30
HK1155170A1 (en) 2012-05-11
CA2726508A1 (en) 2009-12-23
US20110166139A1 (en) 2011-07-07
JP2011524411A (en) 2011-09-01
CN102124000B (en) 2014-09-17
EP2303861B1 (en) 2014-04-23
ZA201100388B (en) 2011-10-26
EA020807B1 (en) 2015-01-30
BRPI0914927A2 (en) 2017-06-20

Similar Documents

Publication Publication Date Title
BRPI0914927B8 (en) compound, pharmaceutical composition and use of a compound
BRPI0611747A2 (en) compound or a pharmaceutically acceptable salt thereof or n-oxides thereof, pharmaceutical composition, methods for treating a bacterial infection and for inhibiting bacterial dna gyrase in a warm-blooded animal, use of a compound or a pharmaceutically acceptable salt thereof, and process for making a compound or a pharmaceutically acceptable salt thereof.
BRPI0805826A2 (en) spiro-substituted compounds as angiogenesis inhibitors, compound production method, pharmaceutical composition and treatment methods
BRPI0507755A (en) substituted pyrazoline compound, process for its manufacture, medicines and their uses
BR112012009376B8 (en) solid pharmaceutical composition comprising a sglt-2 inhibitor and its pharmaceutical dosage form
BRPI0507790A (en) substituted pyrazoline compound, process for its manufacture, medicines and their uses
BRPI0808764B8 (en) spiro-substituted compounds as angiogenesis inhibitors their production process and pharmaceutical composition
BRPI0514691A (en) compound or a pharmaceutically acceptable salt thereof, process for preparing it, pharmaceutical composition, and use of a compound or pharmaceutically acceptable salt thereof
BR112016002496A2 (en) compound of formula i, pharmaceutical composition, method for inhibiting kdm1a, method for treating a globin-mediated disease, method for achieving an effect on a patient, and method for inhibiting at least one function of kdm1a
BR112013022789A2 (en) pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor
BRPI0518126A (en) compound, process for preparing same, pharmaceutical composition, use of a compound, and methods for producing a b-raf inhibitory effect and an anti-cancer effect on a warm-blooded animal, and for treating a disease or condition
BR112012010270A2 (en) mentisulfonylmethane (msm) for treatment of drug resistant microorganisms
BR112014016672A2 (en) carbamate compounds and their preparation and use
BR112015014372A8 (en) autotaxin inhibitors, their uses, and pharmaceutical composition and combination ".
BR112013026834A2 (en) compound, pharmaceutical composition, combination pharmaceutical product, use of a compound, and method for treating diseases or conditions and for inhibiting bromodomain
BR112015007083A2 (en) histone demethylase inhibitors
ATE487720T1 (en) 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS
BRPI0507801A (en) substituted azetidine compounds, process for preparing substituted azetidine compounds, medicament and use of at least one substituted azetidine compound
UA104988C2 (en) Novel pyrone-indole derivatives and process for their preparation
BR112017026535A2 (en) compound of formula I, isolated enantiomer, pharmaceutical composition, method for inhibiting mct4 monocarboxylate transporter activity, method for selectively inhibiting mct4 monocarboxylate transporter activity, method for treating a mct4 monocarboxylate transporter mediated disorder and use of a compound
RU2012157473A (en) METHOD FOR IDENTIFICATION OR TREATMENT OF REACTION "TRANSPLANT AGAINST THE OWNER"
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
BR112014006223A2 (en) 6-substituted-3- (quinolin-6-ylthio) - [1,2,4-triazol [4,3-a] pyradines as c-met tyrosine kinase
BRPI0610090A2 (en) combination therapy comprising diary ureas to treat diseases
CL2021001944A1 (en) Amino acid derivatives for the treatment of inflammatory diseases

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF